CTOs on the Move


 
Emocha uses video technology and human engagement to empower patients to take every dose of medication as prescribed. emocha facilitates a daily touchpoint for patients in order to expand access to treatment, extend the reach of existing care teams, and retain patients in care. emocha`s turnkey, enterprise adherence solution operates through dose-by-dose observation and clinical assessment of potential administration problems, including technique and side effects. Coupled with daily engagement, support, and incentives, emocha is the first holistic solution to medication non-adherence.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.emocha.com
  • 916 North Charles Street 2120, 12nd Floor - Suite 200
    Baltimore, MD USA 21221
  • Phone: 410.864.8587

Executives

Name Title Contact Details
Ramon Castro
Chief Technology Officer Profile
Gorkem Sevinc
Chief Technology Officer and Co-Founder Profile

Similar Companies

Kaiser Permanente Washington Health Research Institute

Kaiser Permanente Washington Health Research Institute (KPWHRI) is a non-profit research organization that conducts practical research to improve the health and health care of Kaiser Permanente members and the public.

First Dental Health

First Dental Health is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rx Trials

Rx Trials is a Ellicott City, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.